VivoSeq
Other

Chronic Liver Failure

19

Pipeline Programs↗

3

Active Trials↗

12

Companies Involved↗

Chronic Liver Failure is an emerging landscape with 19 programs across 12 companies. The most active players are AstraZeneca, Grifols Therapeutics LLC, AbbVie. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

11/100

Mech. Concentration

25/100

Completion Rate

60/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1Grifols Therapeutics LLC logo

Grifols Therapeutics LLC

1 program

Phase 3AbbVie logo

AbbVie

1 program

Phase 3S

Sclnow Biotechnology Co., Ltd.

1 program

Phase 3G

Genzyme, a Sanofi Company

1 program

ApprovedGilead logo

Gilead

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

24 of 26 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody14%Cell therapy14%

Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 29 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed6 · 35%
Unknown status4 · 24%
Not yet recruiting3 · 18%
Terminated2 · 12%
Suspended1 · 6%
Withdrawn1 · 6%

Clinical Trials

Trial Activity

17 trials

National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·Phase 3·NCT07075315·100 enrolled
Safety and Efficacy of Continuous Infusion of Terlipressin With Norepinephrine Versus Norepinephrine Alone in Improving Outcomes of Acute Kidney Injury in Acute on Chronic Liver Failure With Septic Shock
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06556472·126 enrolled
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem Cell Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patient- Phase-II Trial
Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·Phase 2·NCT07131306·100 enrolled
To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02691533·90 enrolled
Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure
Completed·GGovind Ballabh Pant Hospital·Phase 4·NCT01074645·27 enrolled
Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02321371·73 enrolled
High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02719210·75 enrolled
Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02689245·64 enrolled
To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02573727·120 enrolled
TRimetazidine for acUte on Chronic Liver Failure STudy
Suspended·—·Phase 1·NCT03737448·30 enrolled
Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)
Terminated·CCellaion SA·Phase 2·NCT04229901·133 enrolled
To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase
Terminated·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02788240·14 enrolled
To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).
Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03162419
Efficacy and Safety of Hemoperfusion or Plasma Exchange Compared to Standard Medical Therapy in Patients With Acute on Chronic Liver Failure
Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04013113·250 enrolled
Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).
Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03754400·200 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)